Harbour BioMed has acquired common stock in Spruce Biosciences Inc., now holding approximately 3.8% of total outstanding shares and about 3.1% of fully diluted shares. The warrant was exercised by Harbour BioMed’s subsidiary, originally issued as part of a collaboration agreement between HBM Alpha Therapeutics and Spruce. The focus of the collaboration is on advancing the development of SPR202, a monoclonal antibody for treating disorders like congenital adrenal hyperplasia. This strategic move strengthens Harbour BioMed’s position in the biotechnology sector and highlights its commitment to advancing innovative therapies.

Read more at Nasdaq Inc.: Harbour BioMed Exercises Warrant To Acquire Stake In Spruce Biosciences